CompletedPhase 3NCT00391131
Subcutaneous Ig NextGen 16% in PID Patients
Studying Primary immunodeficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CSL Limited
- Principal Investigator
- Marianne Empson, DrAuckland City Hospital
- Intervention
- IgNextGen 16%(drug)
- Enrollment
- 35 enrolled
- Eligibility
- 3 years · All sexes
- Timeline
- 2007 – 2009
Study locations (12)
- The Canberra Hospital, Garran, Australian Capital Territory, Australia
- John Hunter Hospital, New Lambton Heights, New South Wales, Australia
- Sydney Children's Hospital, Randwick, New South Wales, Australia
- Royal Adelaide Hospital, Adelaide, South Australia, Australia
- Women's & Children's Hospital, North Adelaide, South Australia, Australia
- Frankston Hospital, Frankston, Victoria, Australia
- Royal Children's Hospital, Melbourne, Victoria, Australia
- Princess Margaret Hospital for Children, Perth, Western Australia, Australia
- Auckland Hospital, Auckland, New Zealand
- Starship Children's Hospital, Auckland, New Zealand
- Christchurch Hospital, Christchurch, New Zealand
- Wellington Hospital, Wellington, New Zealand
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00391131 on ClinicalTrials.govOther trials for Primary immunodeficiency
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE4NCT07076446An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)CSL Behring
- RECRUITINGPHASE1, PHASE2NCT06839456Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCTChildren's Hospital of Philadelphia
- RECRUITINGNCT06565078A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary ImmunodeficiencyTakeda
- RECRUITINGNANCT07261891Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disordersprof. dr. Rik Schrijvers
- ENROLLING BY INVITATIONNCT06144229Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening AccuraciesUniversity of California, Los Angeles
- ACTIVE NOT RECRUITINGPHASE2NCT06549114Leniolisib for Immune Dysregulation in PIDsPharming Technologies B.V.
- RECRUITINGNANCT06659588Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral DeficiencyAssistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07004803Virtual Reality on Pain and Fear Levels of Children With Primary ImmunodeficiencyDr. Hatice Dönmez